(Q43787275)

26 November 2017

title

Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes (English)

1 reference

26 November 2017

main subject

Streptococcus pneumoniae

1 reference

1 reference

Zheng X

1

1 reference

26 November 2017

Johnson C

2

1 reference

26 November 2017

Lu Y

3

1 reference

26 November 2017

Yanagihara R

4

1 reference

26 November 2017

Hollingshead S

5

1 reference

26 November 2017

Crain M

6

1 reference

26 November 2017

Benjamin W Jr

7

1 reference

26 November 2017

Waites KB

8

1 reference

26 November 2017

publication date

1 October 2001

1 reference

International Journal of Antimicrobial Agents

26 November 2017

published in

1 reference

26 November 2017

volume

18

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

373-378

1 reference

Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900416-2

7 January 2021

10.1016/S0924-8579(01)00416-2

Identifiers

DOI

1 reference

26 November 2017

1 reference